DLA Piper represented Seattle-based Adaptive Biotechnologies Corporation in its US$345 million initial public offering. Adaptive is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery.

The DLA Piper team representing Adaptive Biotechnologies was led by partners Tyler Hollenbeck and Andrew Ledbetter (both of Seattle) and associate Kevin Criddle (Phoenix); and included associates Kerra Melvin, Bianca LaCaille, Kelvin Kesse (all of Seattle), Michael Duval, Chris Provera and Steven Autenrieth (all of Phoenix), as well as partners Cisco Palao-Ricketts (Silicon Valley), Lisa Haile (San Diego) and Rebecca McKnight (Austin).

Adaptive's shares commenced trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol "ADPT." Goldman Sachs & Co. LLC, J.P. Morgan and BofA Merrill Lynch acted as joint lead book-running managers for the offering. Cowen and Guggenheim Securities acted as book-running managers for the offering. William Blair and BTIG acted as co-managers for the offering.